Pain
From the Journals
Trump support high in counties with chronic opioid use
Policy to abate the opioid crisis must go beyond the medical model to incorporate socioenvironmental disadvantage factors and health behaviors.
Conference Coverage
For some SUD patients, kratom may be a self-treatment tool
SAN DIEGO – A survey finds that most users are not consuming kratom “primarily for achieving recreational ‘highs.’ ”
Conference Coverage
Do free meals to physicians affect opioid prescribing?
SAN DIEGO – Physicians who received 1 free meal made about 150 opioid claims; those who received more than 10 made more than 700 claims.
FDA/CDC
Generic versions of Suboxone approved for opioid dependence
The FDA says patients who receive medication-assisted treatment for opioid use disorder reduce their risk of death from all causes by 50%.
Conference Coverage
Mobile app engages individuals with opioid use disorders
Participants’ scores on the medication-assisted treatment attitudes scale rose from a mean of 3.3 to a mean of 3.5 (P = 0.044).
From the Journals
Most U.S. buprenorphine prescribers assess patients for diversion
More than 80% of prescribers are willing to terminate treatment because of diversion concerns, survey shows.
From the Journals
NIH launches HEAL Initiative to combat opioid crisis
HEAL will expand Advancing Clinical Trials in Neonatal Opioid Withdrawal Syndrome (ACT NOW), a pilot study that will assess the prevalence of...
Feature
AMA: Opioid prescriptions down since 2013
Number of providers registered for prescription drug monitoring programs has tripled since 2014.
FDA/CDC
FDA advisory panelists reject Buvaya for acute pain
HYATTSVILLE, MD. – The 18-1 vote against the buprenorphine sublingual spray for moderate to severe pain is based on concerns about side effects....
Conference Coverage
VIDEO: Pills alone not the answer for pain management
SANDESTIN, FLA. – A variety of approaches to pain management is absolutely crucial in the area of opioid abuse.
FDA/CDC
FDA approves Aimovig for migraine prevention
Aimovig is the first FDA-approved treatment to prevent migraines by blocking the calcitonin gene–related peptide receptor.